Veltassa

Swiss healthcare group Galenica has agreed to acquire Relypsa Inc (NASDAQ: RLYP) for $1.53 billion. Relypsa received two downgrades from analysts citing the offer being fair and the low probability of another bidder emerging. Citi Citi’s Yigal Nochomovitz downgraded the rating on the...

Wedbush has maintained its Outperform rating and $51 price target on Relypsa Inc (NASDAQ: RLYP), saying that the sixth full month of Veltassa's launch figures show growth in all categories, including revenue-generating outpatient prescriptions. Veltassa is a potassium binder approved for the...

In late May, shares of Relypsa Inc (NASDAQ: RLYP) soared when the FDA rejected AstraZeneca plc (ADR) (NYSE: AZN)’s hyperkalemia drug ZS-9. The market is betting that the rejection will be good news for Relypsa’s Veltassa, which also treats hyperkalemia. Slingshot Insights recently held...

Relypsa Inc (NASDAQ: RLYP) reported that paid prescriptions for Veltassa in hyperkalemia increased to 1,230 in May, from 928 in April, and that 1,385 free starter packs were dispensed, representing a 14 percent increase from April. BTIG’s Timothy Chiang maintained a Buy rating on the...

Shares of Relypsa Inc (NASDAQ: RLYP) were volatile Thursday morning. The company is the central focus of The Street Sweeper's latest short thesis. The Street Sweeper's Sony Colberg offered eight reasons why investors should consider running away from the stock and not "join this...

Shares of Relypsa Inc (NASDAQ: RLYP) surged higher by more than 30 percent early Friday morning on no corporate news or rumors. According to the TheStreet'sAdam Feuerstein, Relypisa scored a "big win" on Friday after its chief rival AstraZeneca plc (ADR) (NYSE: AZN) confirmed the...

Relypsa Inc (NASDAQ: RLYP) disclosed Veltassa prescription data for April in its 8-K on May 16. Brean Capital’s Difei Yang reiterated a Buy rating on the company, with a price target of $26. April Prescription Data “The numbers, including retail and non-retail TRx, were solid, though...

On its 1Q call, Relypsa Inc (NASDAQ: RLYP) highlighted the challenges it had been facing in gaining patient access for its hyperkalemia treatment, Veltassa. BTIG’s Timothy Chiang maintains a Buy rating on the company, while lowering the price target from $45 to $35. Estimates Lowered Chiang...

Relypsa Inc (NASDAQ: RLYP) shares plunged more than 18 percent after Mizuho Securities downgraded the stock to Underperform from Neutral, saying the near-term buyout of the company is "unlikely" following its recent $150 million debt offering. "We view this event (offering) as a sign that near-term...

Morgan Stanley’s AlphaWise survey revealed that awareness and current treatment patterns remained significant headwinds for Veltassa, the lead product of Relypsa Inc (NASDAQ: RLYP). Morgan Stanley’s Andrew S. Berens maintains an Underweight rating for the company, with a price target of...

The share price of Relypsa Inc (NASDAQ: RLYP) has declined 32.09 percent over the past one month, following a 42.17 percent appreciation over the past three months. Cowen’s Eric Schmidt has maintained an Outperform rating on the company. Data from the drug-drug interaction study for...

Relypsa Inc (NASDAQ: RLYP) shares are up more than 16 percent on Friday afternoon after unconfirmed reports that Merck & Co., Inc. (NYSE: MRK) could make a bid for the $1.07 billion bio therapeutic company. A source familiar with the matter told Benzinga Merck is not involved with a bid, but...